Active substance
Aciclovir
- SFDA 43
- US FDA 100
- Health Canada 19
- US price lines 7
- NHS prices 11
- WHO EML 3
- Safety 8
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ACYCLOVIR JPI 250 mg vial | 250 mg | Sterile, lyophilized, white powder · Intravenous use | 5 Vial | SAR 96.75 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ACYCLOVIR JPI 500 mg vial | 500 mg | Sterile, lyophilized, white powder · Intravenous use | 5 Vial | SAR 193.50 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Aciclovir Dawaa Health | 5 % | Cream · Topical | 1 Tube | SAR 12.15 | Generic · Prescription | Al Dawaa Medical Services Co Ltd | Valid |
| Aciclovir Dawaa Health | 5 % | Cream · Topical | 1 Tube | SAR 25.35 | Generic · Prescription | Al Dawaa Medical Services Co Ltd | Valid |
| Acyclovir - Vaxcel | 250 mg | Powder for infusion · Intravenous use | 10 Vial | SAR 193.50 | Generic · Prescription | Kotra pharma M Sdn Bhd | Valid |
| CLOVIR 200MG TAB | 200 mg | Tablet · Oral use | 100 Blister | SAR 267.80 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CLOVIR 5% CREAM | 5 % | Cream · Topical | 1 Tube | SAR 25.35 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CLOVIRAX 5% cream | 5 % | Cream · Topical | 1 Tube | SAR 25.35 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| CLOVIRAX 5% cream | 5 % | Cream · Topical | 1 Tube | SAR 12.15 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| DEFORAX 5% CREAM | 5 % | Cream · Topical | 1 Tube | SAR 25.35 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| DEFORAX 5% CREAM | 5 % | Cream · Topical | 1 Tube | SAR 12.65 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| IMAVIR 5% CREAM | 5 % | Cream · Topical | 1 Tube | SAR 12.65 | Generic · Prescription | Amman Pharmaceutical Industries (API) | Valid |
| IMAVIR 5% CREAM | 5 % | Cream · Topical | 1 Tube | SAR 38.00 | Generic · Prescription | Amman Pharmaceutical Industries (API) | Valid |
| LOVRAK 200 mg suspension | 40 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 71.95 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| LOVRAK 250MG POWDER FOR I.V. INFUSION | 250 mg | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 21.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| LOVRAK 5% OINTMENT | 5 % | Ointment · Topical | 1 Tube | SAR 25.35 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| LOVRAK 5% cream | 5 % | Cream · Topical | 1 Tube | SAR 25.35 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| LOVRAK 800 mg tablet | 800 mg | Film-coated tablet · Oral use | 20 Blister | SAR 121.10 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| NOVIRAX CREAM 15 GM | 5 % | Cream · Topical | 1 Tube | SAR 38.00 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| SAVIR 5% cream | 5 % | Cream · Topical | 1 Tube | SAR 38.00 | Generic · Prescription | SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| VIROL | 5 % | Cream · Topical | 1 Tube | SAR 25.35 | Generic · Prescription | RIYADH PHARMA | Valid |
| VIRUSTAT 200MG TAB | 200 mg | Tablet · Oral use | 30 Blister | SAR 80.35 | Generic · Prescription | Ram Pharmaceutical Industries | Valid |
| ZOVIRAX | 5 % | Cream · Topical | 1 Tube | SAR 25.35 | NCE · Prescription | Glaxo Saudi Arabia Ltd | Valid |
| ZOVIRAX | 5 % | Cream · Topical | 1 Tube | SAR 16.30 | NCE · Prescription | Glaxo Saudi Arabia Ltd | Valid |
| ZOVIRAX | 800 mg | Tablet · Oral use | 35 Blister | SAR 235.45 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
18 more — full table
Indications — CHI Daman Drug Formulary
ANTIMICROBIAL PROPHYLAXIS IN CANCER PATIENTS; CHICKENPOX (VARICELLA); HERPES SIMPLEX VIRUS (HERPES LABIALIS); HERPES ZOSTER (SHINGLES); HUMAN IMMUNODEFICIENCY VIRUS; MULTIPLE MYELOMA; Septic Shock
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZOVIRAX | 5% | ointment · topical | BAUSCH | Prescription | 29 Mar 1982 |
| ACYCLOVIR | 400MG; 800MG | tablet · oral | TEVA | Prescription | 22 Apr 1997 |
| ACYCLOVIR | 200MG | capsule · oral | TEVA | Prescription | 22 Apr 1997 |
| ACYCLOVIR | 200MG/5ML | suspension · oral | ACTAVIS MID ATLANTIC | Prescription | 28 Apr 1997 |
| ACYCLOVIR | 200MG | capsule · oral | HERITAGE | Prescription | 31 Oct 1997 |
| ACYCLOVIR | 400MG; 800MG | tablet · oral | HERITAGE | Prescription | 31 Oct 1997 |
| ACYCLOVIR SODIUM | EQ 50MG BASE/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 13 May 1998 |
| ACYCLOVIR | 400MG; 800MG | tablet · oral | AUROBINDO PHARMA USA | Prescription | 28 Sep 1998 |
| ACYCLOVIR | 200MG | capsule · oral | REGCON HOLDINGS | Prescription | 26 Jan 1999 |
| ACYCLOVIR | 400MG; 800MG | tablet · oral | CARLSBAD | Prescription | 30 Apr 1999 |
| ZOVIRAX | 5% | cream · topical | BAUSCH | Prescription | 30 Dec 2002 |
| ACYCLOVIR | 200MG | capsule · oral | APOTEX | Prescription | 28 Sep 2005 |
| ACYCLOVIR | 400MG; 800MG | tablet · oral | APOTEX | Prescription | 29 Sep 2005 |
| ACYCLOVIR | 5% | ointment · topical | PHARMOBEDIENT | Prescription | 3 Apr 2013 |
| ACYCLOVIR SODIUM | EQ 50MG BASE/ML | injectable · injection | EUGIA PHARMA | Prescription | 11 Oct 2013 |
| ACYCLOVIR | 400MG; 800MG | tablet · oral | HETERO LABS LTD V | Prescription | 29 Oct 2013 |
| ACYCLOVIR | 400MG; 800MG | tablet · oral | CADILA PHARMS LTD | Prescription | 15 Nov 2013 |
| ACYCLOVIR | 200MG | capsule · oral | CADILA PHARMS LTD | Prescription | 6 Mar 2014 |
| ACYCLOVIR | 5% | ointment · topical | AMNEAL PHARMS | Prescription | 18 Jun 2014 |
| ACYCLOVIR | 400MG; 800MG | tablet · oral | ZYDUS PHARMS | Prescription | 19 Aug 2014 |
| ACYCLOVIR | 200MG | capsule · oral | CADILA | Prescription | 25 Mar 2016 |
| ACYCLOVIR | 5% | ointment · topical | FOUGERA PHARMS INC | Prescription | 11 May 2016 |
| ACYCLOVIR | 5% | ointment · topical | SUN PHARMA CANADA | Prescription | 21 Dec 2016 |
| ACYCLOVIR | 5% | ointment · topical | GLENMARK SPECLT | Prescription | 31 Jul 2017 |
| ACYCLOVIR | 200MG | capsule · oral | CARLSBAD | Prescription | 16 Aug 2017 |
75 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACYCLOVIR SODIUM INJECTION | 02236926 | 50 MG / ML | SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| ACYCLOVIR SODIUM INJECTION | 02494558 | 50 MG / ML | SOLUTION · INTRAVENOUS | AURO PHARMA INC |
| ACYCLOVIR SODIUM INJECTION | 02531224 | 50 MG / ML | SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| APO-ACYCLOVIR | 02207621 | 200 MG | TABLET · ORAL | APOTEX INC |
| APO-ACYCLOVIR | 02207648 | 400 MG | TABLET · ORAL | APOTEX INC |
| APO-ACYCLOVIR | 02207656 | 800 MG | TABLET · ORAL | APOTEX INC |
| APO-ACYCLOVIR OINTMENT | 02477130 | 5 % / W/W | OINTMENT · TOPICAL | APOTEX INC |
| MINT-ACYCLOVIR | 02524708 | 200 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-ACYCLOVIR | 02524716 | 400 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-ACYCLOVIR | 02524724 | 800 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MYLAN-ACYCLOVIR | 02242463 | 400 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-ACYCLOVIR | 02242464 | 800 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-ACYCLOVIR | 02242784 | 200 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| TARO-ACYCLOVIR | 02522306 | 5 % / W/W | OINTMENT · TOPICAL | TARO PHARMACEUTICALS INC |
| TEVA-ACYCLOVIR | 02285959 | 200 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-ACYCLOVIR | 02285967 | 400 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-ACYCLOVIR | 02285975 | 800 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ZOVIRAX | 00569771 | 5 % / W/W | OINTMENT · TOPICAL | BAUSCH HEALTH, CANADA INC. |
| ZOVIRAX | 02039524 | 5 % / W/W | CREAM · TOPICAL | BAUSCH HEALTH, CANADA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ACYCLOVIR 200 MG CAPSULE | $0.09773 | per EA | 30 Sep 2026 |
| US NADAC | ACYCLOVIR 200 MG/5 ML SUSP | $0.07643 | per ML | 23 Sep 2026 |
| US NADAC | ACYCLOVIR 400 MG TABLET | $0.09623 | per EA | 23 Sep 2026 |
| US NADAC | ACYCLOVIR 5% CREAM | $8.99159 | per GM | 23 Sep 2026 |
| US NADAC | ACYCLOVIR 5% OINTMENT | $0.52214 | per GM | 23 Sep 2026 |
| US NADAC | ACYCLOVIR 5% OINTMENT | $0.34585 | per GM | 23 Sep 2026 |
| US NADAC | ACYCLOVIR 800 MG TABLET | $0.19403 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Aciclovir 200mg dispersible tablets | £1.14 | 25 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 200mg tablets | £1.07 | 25 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 200mg/5ml oral suspension sugar free | £21.77 | 125 ml | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 30mg/g eye ointment | £45.00 | 4.5 gram | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 400mg dispersible tablets | £3.76 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 400mg tablets | £2.53 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 400mg/5ml oral suspension sugar free | £31.00 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 5% cream | £1.88 | 2 gram | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 5% cream | £11.53 | 10 gram | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 800mg dispersible tablets | £4.62 | 35 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Aciclovir 800mg tablets | £2.40 | 35 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 21.1. Ophthalmological preparations > Anti-infective agents · core
Herpes simplex keratitis
Local > Ophthalmological > Ointment: 3% w/w - 6.4.1. Antiherpes medicines · core
Zoster; Herpes simplex infections; Varicella
Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium) | Oral > Liquid: 200 mg per 5 mL (EMLc) | Oral > Solid: 200 mg tablet | Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium) - 5.1.6.2. Medicines for viral central nervous system infections · core
Zoster; Herpes simplex infections; Varicella
Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium) | Oral > Liquid: 200 mg per 5 mL (EMLc) | Oral > Solid: 200 mg tablet | Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)
Safety signals and safety-related labeling changes
- US FDA 12 Nov 2025 ZOVIRAX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 12 Nov 2025 ZOVIRAX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 12 Nov 2025 ZOVIRAX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 16 Jul 2021 AVACLYR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Dec 2020 ZOVIRAX — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Dec 2019 SITAVIG — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Dec 2019 XERESE — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 25 Jan 2019 ZOVIRAX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Combinations containing Aciclovir
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.